LEANBIO SL

Their core work

LEANBIO SL is a Spanish biotech SME specializing in lipid-based nanocarrier formulation and GMP-compliant manufacturing for pharmaceutical applications. Their core work involves engineering liposomal delivery systems capable of crossing biological barriers — including the blood-brain barrier — and developing scalable, green manufacturing processes for nanomedicines. They bring a rare combination of molecular formulation science (lipid self-assembly, peptide targeting) and industrial production capability, which positions them as a bridge between research-stage nanomedicine and regulatory-compliant therapeutics. Their project track record spans rare disease enzyme delivery and open-platform nano-pharmaceutical manufacturing test beds.

What they specialise in

How they've shifted over time

LEANBIO's earliest H2020 work (2017–2020) was tightly scoped around a single disease — Fabry disease — with highly specific technical keywords: liposomal GLA delivery, lipid self-assembly, blood-brain-barrier crossing, and GMP green manufacturing. This points to a company that had developed proprietary formulation technology and was validating it in a defined rare-disease context. Their second project (Phoenix, 2021–2025) signals a deliberate broadening: rather than one disease and one nanocarrier, they are now contributing to an open innovation platform for nano-pharmaceuticals across multiple therapeutic areas, suggesting they are generalizing their formulation and manufacturing capabilities into a platform offering.

LEANBIO is moving from rare-disease niche formulation toward a broader nano-pharmaceutical manufacturing services model, likely positioning as a specialist CDMO (contract development and manufacturing organization) for lipid nanoparticle-based therapeutics.

How they like to work

LEANBIO has participated exclusively as a consortium partner rather than a project coordinator, which is consistent with an SME that contributes specialized technical capabilities within programs assembled by larger academic or industrial leads. Their 21 unique partners across 9 countries in just two projects indicates they routinely work within large, multi-stakeholder consortia. This suggests they are well-practiced at integrating their formulation and manufacturing expertise into complex collaborative programs without taking on administrative leadership.

With 21 unique partners across 9 countries from only two projects, LEANBIO operates within large, internationally diverse consortia — likely including pharmaceutical companies, nanomedicine research groups, hospitals, and regulatory bodies. Their network is European in reach but concentrated in the nanomedicine and pharmaceutical manufacturing ecosystem.

What sets them apart

LEANBIO occupies an uncommon position as a small company that combines deep scientific expertise in lipid nanocarrier design with actual GMP manufacturing capability — a combination that most academic nanomedicine groups cannot offer. For consortia working on translational nanomedicine, this makes them a high-value partner at the production readiness stage, where scientific promise must be converted into manufacturable, regulatory-compliant product. Their demonstrated experience with barrier-crossing delivery (blood-brain barrier, cellular membrane) further differentiates them in projects targeting CNS or intracellular disease targets.

Highlights from their portfolio

• Smart-4-Fabry
  Tackled one of the hardest delivery challenges in rare disease — getting enzyme replacement across the blood-brain barrier using a targeted liposomal nanocarrier, while simultaneously developing a GMP-compliant green manufacturing process.
• Phoenix
  LEANBIO's largest project by EC funding (€1.67M), this Innovation Action positions them inside a pan-European open test bed for nano-pharmaceutical products, signaling a strategic move toward platform-level manufacturing services.